יחס חוב להיוון בספרים: Genelux Corp. (GNLX)

Current price action for Genelux Corporation (GNLX) on the GURU.Markets platform accompanies a period of expansion in clinical trials for the treatment of advanced-stage tumors, with the indicator standing at 0.16. The business relies on the Olvi-Vec system, where engineered viruses destroy neoplasms and trigger an immune response. Development is being conducted in collaboration with specialized scientific centers to perform comprehensive tests of new therapy methods.

For Genelux Corporation (GNLX), which invests in high-tech oncolytic therapy, the current balance sheet leverage ratio reflects the balance between R&D capital expenditures and financial stability. This metric is calculated as the ratio of total liabilities to the book value of equity, allowing investors to assess the actual degree of corporate indebtedness and the risk of profit loss resulting from excessive debt reduction.